胸部放疗与免疫检查点抑制同时或序贯给药的安全性比较
本研究在本中心纳入79例接受PD-1、PD-L1和/或CTLA-4抑制剂并接受胸部放疗的患者,将两种治疗间隔1个月内定义为同时(35例,44%),间隔6个月内定义为序贯(44例,56%)。主要终点为与胸部放疗相关的≥2级不良事件(肺炎、其他肺部事件、食管炎、皮炎、乏力)。同时与序贯治疗相比这些不良事件无统计学显著差异;免疫治疗药物类别与≥2级食管炎相关(P = .04)。作者认为≥2级不良事件发生率符合预期且可接受,同时免疫治疗与胸部放疗可能是安全的。
要点
- 同时与序贯胸部放疗和免疫检查点抑制的≥2级不良事件率无统计学显著差异。
- ≥2级不良事件包括肺炎5例(6%)、食管炎6例(8%)、皮炎8例(10%)。
- 免疫治疗药物类别与≥2级食管炎相关(P = .04)。
核心结论
- 胸部放疗与免疫治疗的≥2级不良事件发生率符合预期且可接受;同时与序贯治疗的不良事件率无显著差异,提示即使同时给予免疫治疗和胸部放疗也可能是安全的。
研究设计与样本
- 本研究为本中心患者与治疗特征收集研究,纳入接受PD-1、PD-L1和/或CTLA-4抑制剂并接受胸部放疗的患者共79例。
- 两种治疗间隔1个月内为同时组(35例,44%),间隔6个月内为序贯组(44例,56%)。
- 主要终点为联合治疗(免疫治疗和放疗)相关的≥2级不良事件,具体为肺炎、其他肺部事件、食管炎、皮炎和乏力。
- 进一步进行单因素分析比较不良事件率与临床及治疗相关变量。
主要发现
- 79例患者中,肺癌45例、黑色素瘤15例为最常见原发组织学类型。
- 62例(78%)接受抗PD-1或抗PD-L1抗体,12例(15%)接受抗CTLA-4抗体,5例(6%)同时接受抗PD-1/PD-L1和抗CTLA-4抗体。
- 幸存者中位随访时间为5.9个月(范围2.4-55.6个月)。
- ≥2级不良事件包括肺炎5例(6%)、食管炎6例(8%)、皮炎8例(10%)。
- 同时与序贯治疗相比这些不良事件无统计学显著相关;唯一显著变量为免疫治疗药物类别与≥2级食管炎相关(P = .04)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to evaluate adverse events (AEs) in patients who received both immune checkpoint inhibitors and thoracic radiation therapy (RT). In particular, we compared the rate of toxicities of concurrent versus sequential delivery of thoracic RT and checkpoint inhibitors. METHODS AND MATERIALS: Patient and treatment characteristics were collected on all patients at our institution who were treated with programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and/or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and underwent thoracic RT (n = 79). Receiving both treatments within 1 month was considered concurrent (n = 35; 44%), and any treatment up to 6 months apart was considered sequential (n = 44; 56%). The primary endpoint of this study was the rate of Grade ≥2 AEs from combination therapy (immunotherapy and RT), specifically those that are relevant to thoracic RT: Pneumonitis, other pulmonary events, esophagitis, dermatitis, and fatigue. Further univariate analysis was performed to compare AE rates with clinical and therapy-related variables. RESULTS: A total of 79 patients were identified, with lung cancer (n = 45) and melanoma (n = 15) being the most common primary histology. Sixty-two (78%) patients were treated with anti-PD-1 or anti-PD-L1 antibodies, 12 (15%) with anti-CTLA-4 antibodies, and 5 (6%) received both anti-PD-1/PD-L1 and anti-CTLA-4 antibodies. The median follow-up for survivors was 5.9 months (range, 2.4-55.6 months). Grade ≥2 AEs included pneumonitis (n = 5; 6%), esophagitis (n = 6; 8%), and dermatitis (n = 8; 10%). No statistically significant correlation was found between these AEs when comparing concurrent versus sequential treatment. The only significant variable was a correlation of immunotherapy drug category with Grade ≥2 esophagitis (P = .04). CONCLUSIONS: Overall, Grade ≥2 AE rates of thoracic RT and immunotherapy appeared as expected and acceptable. The lack of significant differences in AE rates with concurrent versus sequential treatment suggests that even concurrent immunotherapy and thoracic RT may be safe.
引用
- von Reibnitz D, Chaft JE, Wu AJ, et al. Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Adv Radiat Oncol. 2018. PMID: 30202807. doi:10.1016/j.adro.2018.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。